19:37 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a...
18:22 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting β-catenin in combination with Xtandi enzalutamide could help treat prostate cancer. In tumor samples from prostate cancer patients, levels of β-catenin were higher...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting Wnt/ CTNNB1 signaling could help treat nodular fasciitis, alveolar rhabdomyosarcoma and other USP6-overexpressing cancers. Screening of siRNA libraries in HEK cells and a human sarcoma...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Company News

Marina Biotech, Microlin Bio deal

Microlin will acquire “substantially all” of Marina’s assets for $1 million in cash and 6.7 million shares valued at $10.1 million based on Microlin’s close of $1.50 before the deal was announced. The deal includes...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML) b-Catenin (CTNNB1); interferon regulatory factor 8 (IRF8) In vitro and mouse studies suggest simultaneously increasing IRF8 expression and inhibiting CTNNB1 could...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer b-Catenin (CTNNB1); HER2 (EGFR2; ErbB2; neu); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) In vitro and mouse studies suggest...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Company News

Marina Biotech cancer news

Marina reduced the size of its board to three from six and said President and CEO J. Michael French will replace James Karis as chairman. Additionally, Marina negotiated with unsecured creditors and issued about 3.2...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Marina Biotech cancer news

Marina said it furloughed about 90% of its employees and ceased most day-to-day operations, including the Phase Ib/IIa START-FAP trial evaluating CEQ508 in patients with familial adenomatous polyposis (FAP). Additionally, the company issued five-year warrants...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Marina Biotech, Cambridge Biolabs LLC deal

Cambridge Biolabs returned rights to use Marina's transKingdom RNAi (tkRNAi) delivery technology for agriculture and veterinary uses. Cambridge Biolabs will retain exclusive rights to use the technology for undisclosed veterinary applications, for which Marina is...